A novel mRNA cancer vaccine helps reduce the chances of melanoma patients' tumors returning
Moderna and Merck released Phase 3 results early after data from their personalized mRNA melanoma vaccine study leaked ahead of an ESMO presentation.
TL;DR
- The companies said vaccine plus pembrolizumab reduced recurrence-or-death risk by 42% compared with pembrolizumab alone.
- The trial involved patients with resected high-risk melanoma; the vaccine is individualized using tumor mutations.
- The results are not an approval, and the companies are discussing regulatory next steps.
Moderna and Merck released INTerpath-001 Phase 3 results on October 22, earlier than planned after data appeared publicly before the ESMO presentation. The trial evaluated an individualized mRNA vaccine alongside pembrolizumab after melanoma surgery. [1] [2]
Reuters reported a 42% reduction in recurrence-or-death risk compared with pembrolizumab alone. The vaccine is designed around mutations identified in each patient’s tumor. [2] [3]
AP reported that the companies were discussing next steps with regulators. The early release followed a leak, with a fuller scientific account scheduled for the congress. [1] [3]
The reported endpoint is recurrence or death, not demonstrated overall-survival benefit. The sources do not report an approval or establish how regulators will assess the complete dataset. [1] [2]
Why it matters
The results add late-stage evidence to a personalized cancer-vaccine approach, while leaving the regulatory path and broader clinical benefit unresolved.
Editor's note
Cross-checked with AP, Reuters and Fierce Biotech. Recurrence-or-death risk is not described as overall survival; no treatment advice.